Given the complex interplay between the vasculature and immune systems, and the immunosuppressive role of VEGF and other angiogenic molecules (e.g., FGF2) in the tumor microenvironment [79], it cannot be excluded that variation in angiogenesis genes may contribute to the modulation of these processes, affecting the response to the above-mentioned therapies. This evidence concerns the gene VEGFA and neoplasm.